Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy.
Delay-Goyet P, Blanchard V, Schussler N, Lopez-Grancha M, Ménager J, Mary V, Sultan E, Buzy A, Guillemot JC, Stemmelin J, Bertrand P, Rooney T, Pradier L, Barnéoud P. Delay-Goyet P, et al. Among authors: rooney t. Alzheimers Dement (N Y). 2016 Nov 3;2(4):267-280. doi: 10.1016/j.trci.2016.10.002. eCollection 2016 Nov. Alzheimers Dement (N Y). 2016. PMID: 29067314 Free PMC article.
High-throughput 3D whole-brain quantitative histopathology in rodents.
Vandenberghe ME, Hérard AS, Souedet N, Sadouni E, Santin MD, Briet D, Carré D, Schulz J, Hantraye P, Chabrier PE, Rooney T, Debeir T, Blanchard V, Pradier L, Dhenain M, Delzescaux T. Vandenberghe ME, et al. Among authors: rooney t. Sci Rep. 2016 Feb 15;6:20958. doi: 10.1038/srep20958. Sci Rep. 2016. PMID: 26876372 Free PMC article.
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse D, Malanda A, Peyronel JF, Evanno Y, Lardenois P, De-Peretti D, Abécassis PY, Barnéoud P, Brunel P, Burgevin MC, Cegarra C, Auger F, Dommergue A, Lafon C, Even L, Tsi J, Luc TPH, Almario A, Olivier A, Castel MN, Taupin V, Rooney T, Vigé X. Lesuisse D, et al. Among authors: rooney t. Bioorg Med Chem Lett. 2019 Apr 1;29(7):929-932. doi: 10.1016/j.bmcl.2019.01.024. Epub 2019 Jan 30. Bioorg Med Chem Lett. 2019. PMID: 30773432
Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T. Lesuisse D, et al. Among authors: rooney t. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. doi: 10.1016/j.bmcl.2010.01.114. Epub 2010 Jan 25. Bioorg Med Chem Lett. 2010. PMID: 20167481
Design of potent and selective GSK3beta inhibitors with acceptable safety profile and pharmacokinetics.
Lesuisse D, Tiraboschi G, Krick A, Abecassis PY, Dutruc-Rosset G, Babin D, Halley F, Châtreau F, Lachaud S, Chevalier A, Quarteronet D, Burgevin MC, Amara C, Bertrand P, Rooney T. Lesuisse D, et al. Among authors: rooney t. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2344-9. doi: 10.1016/j.bmcl.2010.01.132. Epub 2010 Feb 2. Bioorg Med Chem Lett. 2010. PMID: 20189807
212 results